dievini Hopp BioTech holding GmbH & Co. KG
Apogenix’ lead investor is the family of SAP co-founder Dietmar Hopp, whose biotechnology portfolio is managed by dievini Hopp BioTech holding GmbH & Co. KG. dievini is an active investor in life and health sciences companies in Germany and Europe. The focus of dievini’s investments is on innovative therapeutics and diagnostics that have the potential to provide entirely new, more effective, and more tolerable treatment options for patients with life-threatening diseases.
Thanks to the long-term financial commitment of Dietmar Hopp and his family, Apogenix was able to advance its lead drug candidate APG101 from the research lab to the successful completion of a phase II clinical trial in glioblastoma.
German Cancer Research Center (DKFZ)
Apogenix is a spin-out of the renowned German Cancer Research Center (DKFZ) in Heidelberg – the largest biomedical research institute in Germany. Apogenix has concluded a comprehensive licensing agreement with DKFZ covering the exclusive worldwide rights to develop and market APG101.
dievini, DKFZ, the founders, and the management board of Apogenix have all participated in the financing rounds of the company.